Dermatomyositis Drug Market Trends, Size, Competitive Analysis and Forecast 2021-2027
The global dermatomyositis drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Dermatomyositis is a rare disease that is used to describe muscle and skin symptoms. It causes muscle inflammation and skin rash. Additionally, it causes muscle inflammation and swelling and is different from other muscle diseases as it also causes skin problems. The major factor driving the demand for dermatomyositis drug is the increasing prevalence of dermatomyositis disease across the globe.
According to the National
Organization for Rare Diseases, dermatomyositis most commonly occurs between
ages 40 to 60, however, it can occur in people of all ages or at any time from
infancy through approximately age 80. Additionally, its prevalence is estimated
at 9.63 cases per million people. Furthermore, its symptoms usually appear
between the ages of 5 to 15 years in children. Moreover, an estimated 3 in
1,000,000 children are affected by juvenile dermatomyositis. Apart from this,
females are affected twice as often as males by this disease. Hence, the
increasing prevalence of dermatomyositis is driving the demand for
dermatomyositis drugs for treatment which in turn is driving the growth of the
market.
To Request a Sample of our Report on Dermatomyositis
Drug Market: https://www.omrglobal.com/request-sample/dermatomyositis-drug-market
Some major players in the market include Pfizer Inc., Eli
Lilly and Company, and Novartis International AG, among others. The market
players are contributing significantly to the growth of the market by the
adoption of various strategies including mergers & acquisitions, geographical
expansion, partnerships and collaborations, and new product launches, to stay
competitive in the market. For instance, in July 2021, Octapharma Group
announced the approval of Octagam 10% from the US FDA. Octagam 10% is an immune
globulin intravenous liquid preparation indicated for the treatment of
dermatomyositis in adults.
Market Coverage
• The
market number available for – 2020-2027
• Base
year- 2020
• Forecast
period- 2021-2027
Segment Covered-
•
By Type
•
By Application
Regions Covered-
•
North America
•
Europe
•
Asia-Pacific
•
Rest of the World
Competitive Landscape- Pfizer Inc., Eli
Lilly and Company, and Novartis International AG, among others.
(Get 15% Discount on Buying this Report)
A
full Report of Dermatomyositis Drug Market is Available @ https://www.omrglobal.com/industry-reports/dermatomyositis-drug-market
Global Dermatomyositis Drug Market Report by Segment
By Type
• Abatacept
• Baricitinib
• Dalazatide
• Immune
Globulin
• IMO-8400
By Application
• Hospital
• Clinic
• Others
Global Dermatomyositis Drug Market Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment